A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma
Status:
Completed
Trial end date:
2017-08-01
Target enrollment:
Participant gender:
Summary
This study adopts a novel strategy for first-line treatment of osteosarcoma by combining
chemotherapy with anti-angiogenic therapy using bevacizumab (Avastin®), a humanized
monoclonal antibody against vascular endothelial growth factor (VEGF). Chemotherapy for
localized disease comprises a 3-drug regimen (cisplatin, doxorubicin, and high-dose
methotrexate). Chemotherapy for metastatic or unresectable disease comprises a
cisplatin-based regimen that includes high-dose methotrexate, doxorubicin, ifosfamide, and
etoposide.